Chlorambucil and cyclosporine a in Brazilian patients with behçet's disease uveitis-a retrospective study;Clorambucil e ciclosporina A em pacientes brasileiros com doença de Behçet e uveíte - Estudo retrospectivo

Arquivos Brasileiros de Oftalmologia

Volumn 73, Issue 1, 2010, Pages 40-46

  Zaghetto, Juliana Marques ^a   Yamamoto, Mirian Mina ^a   Souza, Murilo Barreto ^a   da Silva, Felipe Theodoro Bezerra Gaspar Carvalho ^a   Hirata, Carlos Eduardo ^a   Olivalves, Edilberto ^a   Yamamoto, Joyce Hisae ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Beh et syndrome; Chlorambucil therapeutic use; Cyclosporine therapeutic use; Immunosuppressive agents therapeutic use; Retrospective studies; Uveitis therapy

Indexed keywords

CHLORAMBUCIL; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CHILD; FEMALE; FOLLOW UP; HUMAN; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UVEITIS;

ADOLESCENT; ADULT; BEHCET SYNDROME; CHILD; CHLORAMBUCIL; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 77954932504     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492010000100007     Document Type: Article

References (27)

1. Evereklioglu C. Current concepts in the etiology and treatment of Behçet's disease. Surv Ophthalmol. 2005;50(4):297-350. Comment in: Surv Ophthalmol. 2006;51(2):174; author reply 174-7.
2. Gouveia EB, Yamamoto JH, Abdalla M, Hirata CE, Kubo P, Olivalves E. Causas das uveítes em serviço terciário em São Paulo, Brasil. Arq Bras Oftalmol. 2004;67(1):139-45.
3. Ohno S, Ohbuchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol. 1982; 100(9):1455-8.
4. Ando K, Fujino Y, Hijikata K, Izawa Y, Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol. 1999;43(4):312-7.
5. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet's disease. Ophthalmology. 1995; 102(2):317-21. Comment in: Ophthalmology. 1995;102(12):1739.
6. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-80.
7. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol. 1970; 84(4):451-2.
8. Abdalla MI, El-D Bahoat N. Long-lasting remission of Behçet's disease after chlorambucil therapy. Br J Ophthalmol. 1973;57(9):706-11.
9. Patapanian H, Graham S, Sambrook PN, Browne CD, Champion GD, Cohen ML, et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol. 1988;27(1):44-7.
10. Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983;2(8344):235-8.
11. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Doublemasked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1(8647):1093-6.
12. Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sightthreatening ocular inflammation. Ophthalmology. 2002;109(2):370-7.
13. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-a multicenter study. The Behçet's Disease Research Committee of Japan. J Rheumatol. 1989;16(4): 506-11.
14. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2): 180-4. Comment in: Br J Ophthalmol. 2007;91(2):133-4.
15. Marin ML, Savioli CR, Yamamoto JH, Kalil J, Goldberg AC. MICA polymorphism in a sample of the São Paulo population, Brazil. Eur J Immunogenet. 2004;31(2):63-71.
16. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16.
17. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986;70(8):589-92.
18. Tricoulis D. Treatment of Behçet's disease with chlorambucil. Br J Ophthalmol. 1976;60(1):55-7.
19. Tabbara KF. Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology. 1983;90(8):906-8.
20. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513. Comment in: Am J Ophthalmol. 2001;131(5):679.
21. Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146(6):802-12.
22. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109(1):137-42.
23. Müftüo{eth}lu AU, Pazarli H, Yurdakul S, Yazici H, Ulkü BY, Tüzüun Y, et al. Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol. 1987;71:387-90.
24. Süllü Y, Öge I, Erkan D, Aritürk N, Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand. 1998;76(1):96-9.
25. Atmaca LS, Batioglu F. The efficacy of cyclosporin-A in the treatment of Behçet's disease. Ophthalmic Surg. 1994;25(5):321-7.
26. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35(5):369-85. Erratum in: Surv Ophthalmol. 1991;35(6):475. Dosage error in article text.
27. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579-82. Comment in: Br J Ophthalmol. 2007;91(12):1573-4